Madelon Q. Wentink

Madelon Q. Wentink

Auto-generated profile, based on publicly available information

Madelon Q. Wentink

Angiogenesis Laboratory, Department of Medical Oncology, Vrije Universiteit Medical Center, 1081 HZ Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MWMadelon Q. Wentink
Madelon Q. Wentink
THTilman M. Hackeng
Tilman M. Hackeng
STSebastien P. Tabruyn
Sebastien P. Tabruyn
WPWouter C. Puijk
Wouter C. Puijk
KSKlaus Schwamborn
Klaus Schwamborn
Peter TimmermanPeter Timmerman
Peter Timmerman
Significance: VEGF is the pivotal growth factor for angiogenesis, and its inhibition by passive immunotherapy results in improved survival in patients with several types of cancer. We believe that the clinical benefit could be increased by inducing a humoral immune response against VEGF through active immunization with VEGF-based peptides. In this study, we describe that correct peptide design is vital for success. We show that only 3D-structured peptides perfectly mimicking the crucial β5–turn–β6 loop of endogenous VEGF are able to induce neutralizing antibodies. We developed a vaccine with potent in vitro and in vivo VEGF-neutralizing activities, as shown in passive and active immunization tumor models. The VEGF vaccination strategy has the potential to outperform current clinical anti-VEGF treatment strategies.

11 April 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MWMadelon Q. Wentink
Madelon Q. Wentink
EHElisabeth J. M. Huijbers
Elisabeth J. M. Huijbers
Peter TimmermanPeter Timmerman
Peter Timmerman
AGArjan Griffioen
Arjan Griffioen
We read with great interest the letter by Marchiò et al. (1) on our recently published paper describing the rational design and testing of a vaccine directed against the major angiogenic growth factor VEGF (2). The letter raises the concern that the potential of the vaccine is limited because of the anaphylactic responses observed in the active vaccination experiments in mice and the incomplete tumor responses observed. The adverse effects observed were most likely because of the high antigen dose (10 mg/kg per immunization) used in the mouse studies. Rats treated with much lower doses (0.5 mg/kg per immunization) lacked such adverse responses. Similarly, extensive studies in cynomolgus monkeys demonstrated the …